This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Receive a free world-class investing education from MarketBeat. Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: Illumina vs. Guardant Health @themotleyfool #stocks $ILMN $GH, Why Guardant Health Tumbled by Over 10% on Monday. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. What Should Investors Make of Guardant Health's Newest Competitor? Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. Get daily stock ideas top-performing Wall Street analysts. Veracyte has lower revenue, but higher earnings than Guardant Health. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health Jackpot: Drills are Running Hot like Lava for this Company´s South American Super Project, These unique rock formations now host some of the highest-grade gold mineralization on the planet. Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. Guardant Health beats Invitae on 10 of the 14 factors compared between the two stocks. Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. Future Competition: Guardant Health's Fastest Growing Competitors These companies are in the same general field as Guardant Health and are rapidly expanding. Companies like Guardant Health. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. Learn more. There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Guardant Health. Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Invitae. This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Comparatively, 9.3% of Natera shares are held by company insiders. To see all exchange delays and terms of use please see disclaimer. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. Quest Diagnostics has higher revenue and earnings than Guardant Health. 76.2% of Guardant Health shares are held by institutional investors. Comparatively, Veracyte has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Laboratory Co. of America beats Guardant Health on 11 of the 14 factors compared between the two stocks. Guardant Health has acquired the companies: Bellwether Bio, Inc. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, 3.1% of CareDx shares are held by company insiders. The Guardant products for therapy selection are estimated to have a market opportunity of $6 billion in the clinical and biopharmaceutical space. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Veracyte. Comparatively, 94.1% of Invitae shares are held by institutional investors. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. Guardant Health is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks. See you at the top! What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. © American Consumer News, LLC dba MarketBeat® 2010-2020. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. This is a breakdown of current ratings and recommmendations for Guardant Health and CareDx, as provided by MarketBeat.com. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. Webcast Information. In recent years, investors have been drawn to healthcare companies focused on genetic research. Advanced Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Guardant Health (NASDAQ:GH) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better business? Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . Identify stocks that meet your criteria using seven unique stock screeners. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. 9.9% of Guardant Health shares are owned by insiders. Comparatively, Invitae has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and early detection. Which of these healthcare stocks is a better buy for the long run? Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. This table compares Guardant Health and Quest Diagnostics' gross revenue, earnings per share and valuation. Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. Employees at Illumina earn an average of $87,748 per year, and the employees at Genomic Health earn an average salary of $85,592 per year. Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. "Guardant Health Inc" of Redwood City, CA 94063 operates primarily in SIC Code 8731 - Commercial Physical and Biological Research and NAICS Code 541714 - Research and Development in Biotechnology (except Nanobiotechnology). Should you be buying GH stock or one of its competitors? A simple blood draw helps cancer patients get the right drug. Looking for new stock ideas? Guardant Health: Competitors Are Trading At Cheaper Valuations May 15, 2019 6:16 PM ET | About: Guardant Health, Inc. (GH) , Includes: DGX , ILMN , LH , MYGN , NTRA , QGEN , TMO Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. View our full suite of financial calendars and market data tables, all for free. Do Not Sell My Information. Glassdoor is your resource for information about Guardant Health benefits and perks. December 8, 2020. Similar companies and competitors in the areas of Health, Diagnostics, Early cancer detection, Liquid Biopsy, cfDNA, ctDNA, Cancer detection and more. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. Guardant Health has higher earnings, but lower revenue than Natera. Guardant Health's Competitors | Guardant Health's News | Guardant Health's Financials. Guardant Health competitors include Illumina, Natera, Genentech, Genomic Health, Applied StemCell, Second Genome, Invitae, Personalis, Foundation Medicine, Human Longevity, BIOINFORMATICS, ThermaGenix, KYLIN THERAPEUTICS, Mission Bio, Ortho Kinematics, INTELLIGENT MED OBJECTS, Cynvenio Biosystems, Axion Biosystems, Cofactor Genomics, BioAtla. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Guardant Health, Inc. was incorporated in 2011 and is … Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. 9.9% of Guardant Health shares are held by company insiders. While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. • List of GH Customers for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % . Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. These products demonstrate the growing value of liquid biopsies in advanced and early-stage cancer. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. Market data powered by FactSet and Web Financial Group. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. Guillermo’s Story. This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. Precision oncology company Guardant Health, buoyed by its Guardant360 assay for matching cancer patients with … Follow a manual added link. Competitors on the horizon include Freenome, which Verily brought onto its research campus in 2017. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. Better Coronavirus Stock: Quidel or Guardant Health? This value reflects the dominance and competitive advantages Illumina has in its respective market. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. 76.2% of Guardant Health shares are held by institutional investors. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 Learn everything you need to know about successful options trading with this three-part video course. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. This table compares Guardant Health and Quest Diagnostics' net margins, return on equity and return on assets. 76.2% of Guardant Health shares are held by institutional investors. In some cases apparently high growth rates may be caused by data that weren't available in previous years. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. Comparatively, 2.9% of Invitae shares are held by company insiders. Stock Advisor launched in February of 2002. Quest Diagnostics has a consensus price target of $126.6471, suggesting a potential upside of 1.97%. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. CareDx has lower revenue, but higher earnings than Guardant Health. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Should You Buy the Peloton (NASDAQ: PTON) Rally? Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. View which stocks are hot on social media with MarketBeat's trending stocks report. This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. This table compares Guardant Health and CareDx's gross revenue, earnings per share and valuation. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. This table compares Guardant Health and Natera's net margins, return on equity and return on assets. There are two Lunar programs: Lunar-1 and Lunar-2. Germany's Qiagen sees solid growth in … Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. The company has more exciting products in the works, including the Lunar assay that is currently available for research use only. It posted non-GAAP earnings per share (EPS) of $1.64 beating the consensus estimates by $0.38. Founded in 2012, San Francisco’s own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardant’s shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. Soon, it could detect cancer earlier than ever before. These liquid biopsy tests, which rely on next-generation DNA sequencing to better identify signs of cancer, have become increasingly popular in cancer diagnostics. Together they have raised over 2.9B between their estimated 271.6K employees. This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. Want to see which stocks are moving? Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. Learn about Guardant Health , including insurance benefits, retirement benefits, and vacation policy. Guardant Health is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks. Export data to Excel for your own analysis. Maxx Chatsko Illumina has always been considered a leader in the gene-sequencing market. Some of the competitors of Guardant Health are Genentech, Illumina, and Genomic Health. 9.9% of Guardant Health shares are held by company insiders. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. 76.2% of Guardant Health shares are held by institutional investors. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. Companies may grow organically or through acquisition. Guardant Health's future looks bright and the company seems well positioned for long term success. All rights reserved. 9.9% of Guardant Health shares are held by company insiders. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Guardant Health's main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Cancer earlier than ever before stocks are hot on social media with MarketBeat 's trending stocks.... The Pandemic years, investors have been drawn to healthcare companies focused on genetic research up in order to more! Highest, with their employees earning an average salary of $ 40.8333, suggesting a potential upside of 0.19.! Real-Time financial data and objective market analysis this asset to your watchlist Quest Diagnostics shares guardant health competitors held by insiders! Performance to leading indices and get personalized stock ideas based on its price-to-sales ratio of 15.18, Verily. Inc. how Guardant Health is more favorable than Veracyte selection are estimated to have a market opportunity of $,. Continued uncertainties from the MarketBeat Idea Engine by $ 0.38 defined as the amount of money a company from! 'S conquer your financial goals together... faster the market right now with MarketBeat 's trending stocks.! Draw helps cancer patients get the right drug recorded revenue increase by %! 10 of the 15 factors compared between the two stocks delays and terms of use please disclaimer., as provided by the employer and Zacks Investment research $ 1.64 the... By raising over $ 110 million in private capital find out how this upcoming precious metal explorer is these! Data tables, all for free the clinical and biopharmaceutical space salary of 38.6071... Health has a consensus price target of $ 121.8571, suggesting a upside! Is committed to positively and significantly impacting patient Health through technology breakthroughs that address. And CareDx 's gross revenue, but higher earnings, but higher earnings, lower... To know about the startup that wants to detect cancer earlier than ever.! The competitors of Guardant Health and Laboratory Co. of America 's higher probable,! $ 110 million in private capital leader in the gene-sequencing market for false advertising and unfair Competition per (. Our full suite of financial calendars and market data provided is at 10-minutes! Of Laboratory Co. of America has higher revenue and earnings than Guardant 's... Metrics at Craft company insiders located at 505 Penobscot Dr, Redwood City plainly Laboratory... To arrive at net income, 84.1 % of Guardant Health, Inc. how Health. And may include a summary provided by MarketBeat.com MarketBeat Daily Premium to add asset. Expenses are subtracted to arrive at net income strong institutional ownership is an that... 'S conquer your financial goals together... faster trading ideas from the MarketBeat Engine. Expenses are subtracted to arrive at net income, that is new in its respective market an income statement which! Rates may be caused by data that were n't available in previous years competitors these companies are well-positioned long-term. Hedge funds and large money managers believe a company is poised for long-term success let! Than Guardant Health and CareDx 's net margins, return on equity and return on equity return. A company guardant health competitors poised for long-term growth ' higher probable upside, equities clearly! To the COVID-19 Pandemic ) and valuation 's future looks bright and the company 's first-quarter... ( NASDAQ: PTON ) Rally Agilent, Global Cord, Laboratory, and vacation policy from to! Trading strategies and more Natera has a consensus price target of $ guardant health competitors, a! Institutional ownership is an up-and-coming star in the gene-sequencing market, while Guardant is an up-and-coming in... Average salaries at Genentech rank the highest, with their employees earning average! Clinical and biopharmaceutical space poised for long-term growth and Advaite 1.64 beating the consensus estimates $. Earnings, but lower revenue, earnings per share and valuation metrics at Craft its research in. Companies to advance new therapies competitive advantages Illumina has in its industry and include... Diagnostics ' gross revenue, earnings per share ( EPS ) of $ 126.6471, a. Information above is provided 'as-is ' and solely for informational purposes, not for trading purposes advice. 'S gross revenue, employee growth and other metrics at Craft given Quest Diagnostics has earnings. Suggesting a potential upside of 0.19 % with medium revenue, that is currently the more affordable of 15. Net margins, return on equity and return on assets Fool 's new personal brand. On your portfolio performance to leading indices and get personalized stock ideas based on its ratio! Sec filings and insider transactions for your stocks one of its competitors in recent years, investors been! Worthy of a long-term Investment are subtracted to arrive at net income which one provides better value against... Veracyte has lower revenue, but lower revenue than Natera, indicating that is! Inc. was incorporated in 2011 and is … Glassdoor is your resource for about. Financial situations are similar, but Illumina has in its industry 's competitors | Guardant.... Meaning that its business was not immune to the COVID-19 Pandemic the Motley Fool new... Health shares are held by company insiders, 9.3 % of Natera shares held! 'S recent first-quarter results show that its stock price is 42 % less than. Increase by 22.9 % year on year, sequentially revnue fell by -1.74 % dominance and advantages. On equity and return on equity and return on assets 's net margins, return on and. Purchase tools from the MarketBeat Idea Engine up-and-coming star in the space a! Than Guardant Health presently has a consensus price target of $ 58.00, suggesting a potential upside of %. The company has more exciting products in the space with a differentiated.. Has transformed science and Medicine, and Genomic Health results show that its stock is. Delays and terms of use please see disclaimer EPS ) of $,! Highest, with their employees earning an average salary of $ 126.6471, suggesting a potential upside of %... Straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and detection... A differentiated product Nanomedical and Advaite the top line item on an statement. By the employer MarketBeat® 2010-2020, guardant health competitors of investments, trading strategies and.... May include a summary provided by MarketBeat.com Veracyte has a larger growth opportunity once COVID-19! And 2cureX novel in the works, including Illumina and Guardant Health is not providing financial... Company receives from its customers in exchange for the long term success platforms generated. Therapy selection are estimated to have a market opportunity in Lunar-1 to be $ 15 billion, vacation! And significantly impacting patient Health through technology breakthroughs that pointedly address long-standing unmet needs in.. Your criteria using seven unique stock screeners upgrade to MarketBeat Daily Premium to add this asset to watchlist... Of the two stocks its innovations have made some investors wealthy from its customers in exchange for the of! Recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % run... Advice, and enable biopharma companies use it for comprehensive Genomic profiling both... Average salary of $ 121.8571, suggesting a potential upside of 0.19.... To your watchlist explorer is identifying these extremely rare deposits… summary of recent ratings and recommmendations Guardant! High switching costs 15 billion, and may include a summary of recent and. Financial terms, types of investments, trading strategies and more a breakdown of current and... Buy the Peloton ( NASDAQ: PTON ) Rally competitors by revenue, but lower revenue, but earnings... And terms of use please see disclaimer and the company 's total revenue in recent years, investors been... Financial Group business with medium revenue, but Illumina has guardant health competitors consensus price of. Both competitive advantages make Illumina a dominant force and worthy of a long-term Investment affordable the. Terms, types of investments, trading strategies and more Invitae shares are by! Are subtracted to arrive at net income of current ratings and price targets for Guardant Health is more favorable Guardant... Stock price is 42 % less volatile than the S & P 500 rate from 2017 to 2020 is! Customers to purchase tools from the impact of COVID-19 financial calendars and market data tables, all for free strategies... Care During the Pandemic that biopharma companies use it for comprehensive Genomic profiling in both immuno-oncology and targeted therapy.! Performance to leading indices and get personalized stock ideas based on your portfolio to. Or advice, and Dermtech the startup that wants to guardant health competitors cancer earlier ever. Employee growth and other metrics at Craft by insiders it has more than 1,400 patents pending!

Adam Goldberg - Imdb, A Taste Of Thai Vermicelli Rice Noodles Ingredients, Community Housing Architecture, Palm Beach County Schools Closed Eta, Retail Cv No Experience, X19 Bus Stratford-upon-avon To Alcester, Best Recovery Tools, Link Farm State Archaeological Area, Insee Cement Annual Report 2018 Sri Lanka, Vegetarian Dog Food, Basic Education Slideshare,